Continuing Education
2024 Year in Review: Updates in Therapy | New IV Medication Approvals
Best Suited For: Pharmacist, Pharmacy Technician
CE Credits: 1 hours
Related Topics: New Drug Approvals
Activity Description
This CE activity will provide pharmacists and pharmacy technicians with a comprehensive overview of newly FDA-approved therapies in 2024. The session will review new oncology drugs, including their mechanisms of action (MOA), indications, safety profiles, dosing and administration instructions, and any withdrawals from the market. Participants will gain knowledge and understanding of these newly approved therapies and their place in clinical practice. Specific intravenous (IV) therapies to be discussed include tislelizumab as monotherapy and in combination with chemotherapy, imetelstat, zolbetuximab, zanidatamab, and zenocutuzumab.
CE Credit: 1 hour
Fee: This activity does not require payment to register.
Learning Objectives
- Review oncology drugs that had their approvals withdrawn in 2024
- Explain the mechanism of action of new IV oncology drug classes
- Summarize clinical trial data that led to the IV oncology drug approvals from 2024
- Describe safety & monitoring of new IV oncology drug approvals from 2024
- Compare place in therapy of new 2024 IV oncology drug approvals with current therapies
Obtaining CE Credit
To receive credit, you must and complete all the steps found in the “Complete Credit Requirements” link provided by the registration confirmation email from LecturePanda You may also use this page to obtain CE credit. After following the link on this page to in order to receive credit:
- Reviewing the course learning materials.
- Confirming information provided on registration.
- Watching the CE video (if it is an enduring or on-demand CE activity) to its entirety
- Submitting the CE Code (disclosed towards the end of all CE activities)
- Completing all listed evaluations and CE assessments.
Credit requirements must be completed before the date of the activity. Upon completion, credit will be transmitted electronically to the ACPE. All transmitted will be viewable in your CPE Monitor profile within 24 hours.
